t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2

Genes Chromosomes and Cancer

Volumn 50, Issue 12, 2011, Pages 996-1009

  Nagel, Stefan ^a   Schneider, Björn ^a   Rosenwald, Andreas ^b   Meyer, Corinna ^a   Kaufmann, Maren ^a   Drexler, Hans G ^a   MacLeod, Roderick A F ^a  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE; SILDENAFIL; SMALL INTERFERING RNA; STAT1 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CHROMOSOME ABERRATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC VARIABILITY; HODGKIN DISEASE; HOMEOBOX; HUMAN; HUMAN CELL; KARYOTYPING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRESSOR GENE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZHX2 GENE;

ADOLESCENT; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 4; CHROMOSOMES, HUMAN, PAIR 8; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, HOMEOBOX; HODGKIN DISEASE; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KARYOTYPE; MALE; MICROARRAY ANALYSIS; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 80053633257     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20920     Document Type: Article

References (52)

1. Abate-Shen C. 2002. Deregulated homeobox gene expression in cancer: Cause or consequence? Nat Rev Cancer 2: 777-785.
2. Abusnina A, Alhosin M, Keravis T, Muller CD, Fuhrmann G, Bronner C, Lugnier C. 2011. Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p 73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cell Signal 23: 152-160.
3. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. 2011. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 221: 248-263.
4. Aleksijevic A, Lang JM, Giron C, Stoclet JC, Mayer S, Oberling F. 1983. Alterations of peripheral blood lymphocyte cyclic AMP and cyclic GMP in untreated patients with Hodgkin's disease. Clin Immunol Immunopathol 26: 398-405.
5. Aleksijevic A, Lugnier C, Giron C, Mayer S, Stoclet JC, Lang JM. 1987. Cyclic AMP and cyclic GMP phosphodiesterase activities in Hodgkin's disease lymphocytes. Int J Immunopharmacol 9: 525-531.
6. Armellini A, Sarasquete ME, García-Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfão A, Gutiérrez NC, González M, San Miguel JF. 2008. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol 141: 212-215.
7. Baus D, Nonnenmacher F, Jankowski S, Döring C, Bräutigam C, Frank M, Hansmann ML, Pfitzner E. 2009. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 23: 1885-1893.
8. Boswell-Smith V, Spina D, Page CP. 2006. Phosphodiesterase inhibitors. Br J Pharmacol 147 (Suppl 1): S252-S257.
9. Döhner H, Bloomfield CD, Frizzera G, Frestedt J, Arthur DC. 1992. Recurring chromosome abnormalities in Hodgkin's disease. Genes Chromosomes Cancer 5: 392-398.
10. Drexler HG. 2011. Guide to Leukemia-Lymphoma Cell Lines, 2nd ed. Braunschweig, Germany: e-book on compact disc.
11. Edgar R, Domrachev M, Lash AE. 2002. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
12. Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Dobbins SE, Lightfoot T, van Leeuwen FE, Försti A, Diepstra A, Broeks A, Vijayakrishnan J, Shield L, Lake A, Montgomery D, Roman E, Engert A, von Strandmann EP, Reiners KS, Nolte IM, Smedby KE, Adami HO, Russell NS, Glimelius B, Hamilton-Dutoit S, de Bruin M, Ryder LP, Molin D, Sorensen KM, Chang ET, Taylor M, Cooke R, Hofstra R, Westers H, van Wezel T, van Eijk R, Ashworth A, Rostgaard K, Melbye M, Swerdlow AJ, Houlston RS. 2011. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet 42: 1126-1130.
13. Fuller JF, McAdara J, Yaron Y, Sakaguchi M, Fraser JK, Gasson JC. 1999. Characterization of HOX gene expression during myelopoiesis: Role of HOX A5 in lineage commitment and maturation. Blood 93: 3391-3400.
14. Harousseau JL, Shaughnessy J, Jr., Richardson P. 2004. Multiple myeloma. Hematology Am Soc Hematol Educ Program 237-256.
15. Hartmann S, Martin-Subero JI, Gesk S, Hüsken J, Giefing M, Nagel I, Riemke J, Chott A, Klapper W, Parrens M, Merlio JP, Küppers R, Bräuninger A, Siebert R, Hansmann ML. 2008. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica 93: 1318-1326.
16. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S, Dörken B, Zenke M, Stein H, Scheidereit C. 2002. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196: 605-617.
17. Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB. 2007. Characterization of early stages of human B cell development by gene expression profiling. J Immunol 179: 3662-3671.
18. Imada K, Leonard WJ. 2000. The Jak-STAT pathway. Mol Immunol 37: 1-11.
19. Iso T, Kedes L, Hamamori Y. 2003. HES and HERP families: Multiple effectors of the Notch signaling pathway. J Cell Physiol 194: 237-255.
20. Joos S, Küpper M, Ohl S, von Bonin F, Mechtersheimer G, Bentz M, Marynen P, Möller P, Pfreundschuh M, Trümper L, Lichter P. 2000. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60: 549-552.
21. Joos S, Siebert R. 2007. Cytogenetics of classical Hodgkin lymphoma. In: Hoppe R, Mauch PM, Armitage JO, editors. Hodgkin Lymphoma. Philadelphia, PA: Wolters Kluwer.
22. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. 2002. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99: 3398-3403.
23. Kanzler H, Hansmann ML, Kapp U, Wolf J, Diehl V, Rajewsky K, Küppers R. 1996. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 87: 3429-3436.
24. Kawata H, Yamada K, Shou Z, Mizutani T, Yazawa T, Yoshino M, Sekiguchi T, Kajitani T, Miyamoto K. 2003. Zinc-fingers and homeoboxes (ZHX) 2, a novel member of the ZHX family, functions as a transcriptional repressor. Biochem J 373: 747-757.
25. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H. 2001. STAT3 is constitutively activated in Hodgkin cell lines. Blood 98: 762-770.
26. Küppers R. 2009. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 491-496.
27. MacLeod RA, Spitzer D, Bar-Am I, Sylvester JE, Kaufmann M, Wernich A, Drexler HG. 2000. Karyotypic dissection of Hodgkin's disease cell lines reveals ectopic subtelomeres and ribosomal DNA at sites of multiple jumping translocations and genomic amplification. Leukemia 14: 1803-1814.
28. MacLeod RA, Nagel S, Kaufmann M, Greulich-Bode K, Drexler HG. 2002. Multicolor-FISH analysis of a natural killer cell line (NK-92). Leuk Res 26: 1027-1033.
29. MacLeod RA, Kaufmann M, Drexler HG. 2007. Cytogenetic harvesting of commonly used tumor cell lines. Nat Protoc 2: 372-382.
30. Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, Anagnostopoulos I, Lietz A, Sigvardsson M, Jundt F, Jöhrens K, Bommert K, Stein H, Dörken B. 2006. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 7: 207-215.
31. Monsalve E, Pérez MA, Rubio A, Ruiz-Hidalgo MJ, Baladrón V, García-Ramírez JJ, Gómez JC, Laborda J, Díaz-Guerra MJ. 2006. Notch-1 up-regulation and signaling following macrophage activation modulates gene expression patterns known to affect antigen-presenting capacity and cytotoxic activity. J Immunol 176: 5362-5373.
32. Nagel S, Scherr M, Quentmeier H, Kaufmann M, Zaborski M, Drexler HG, MacLeod RA. 2005. HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia 19: 841-846.
33. Nagel S, Burek C, Venturini L, Scherr M, Quentmeier H, Meyer C, Rosenwald A, Drexler HG, MacLeod RA. 2007. Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood 109: 3015-3023.
34. Nagel S, Meyer C, Quentmeier H, Kaufmann M, Drexler HG, MacLeod RA. 2008. MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. Leukemia 22: 600-607.
35. Owens BM, Hawley RG. 2002. HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells 20: 364-379.
36. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, Euskirchen G, Bernier B, Varhol R, Delaney A, Thiessen N, Griffith OL, He A, Marra M, Snyder M, Jones S. 2007. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods 4: 651-657.
37. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, Binet JL, Delic J, Merle-Beral H. 2003. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101: 265-269.
38. Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F, Schermuly RT. 2011. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs 19: 117-131.
39. Scheeren FA, Diehl SA, Smit LA, Beaumont T, Naspetti M, Bende RJ, Blom B, Karube K, Ohshima K, van Noesel CJ, Spits H. 2008. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: Evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 111: 4706-4715.
40. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203: 2691-2702.
41. Shah N, Sukumar S. 2011. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10: 361-371.
42. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, Mak TW. 2002. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99: 618-626.
43. Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, Connors JM, Horsman DE, Gascoyne RD. 2011. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 116: 418-427.
44. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ. 2011. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40.
45. Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Mountford JC, Jorgensen HG, Soutar R, Brown R. 2007. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 13: 5048-5055.
46. Weerkamp F, Luis TC, Naber BA, Koster EE, Jeannotte L, van Dongen JJ, Staal FJ. 2006. Identification of Notch target genes in uncommitted T-cell progenitors: No direct induction of a T-cell specific gene program. Leukemia 20: 1967-1977.
47. Wienk H, Lammers I, Hotze A, Wu J, Wechselberger RW, Owens R, Stammers DK, Stuart D, Kaptein R, Folkers GE. 2009. The tandem zinc-finger region of human ZHX adopts a novel C2H2 zinc finger structure with a C-terminal extension. Biochemistry 48: 4431-4439.
48. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mücke S, von Kalle C, Fonatsch C, Schaefer HE, Hansmann ML, Diehl V. 1996. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 87: 3418-3428.
49. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A, Younes A. 2003. MEK/ERK pathway is aberrantly active in Hodgkin disease: A signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102: 1019-1027.
50. Zhu J, Zhang Y, Joe GJ, Pompetti R, Emerson SG. 2005a. NF-YA activates multiple hematopoietic stem cell (HSC) regulatory genes and promotes HSC self-renewal. Proc Natl Acad Sci USA 102: 11728-11733.
51. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. 2005b. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94: 336-350.
52. Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC, Aster JC, Allman D, Pear WS. 2005. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 106: 3898-3906.